The efficacy and drug interactions of Remibrutinib in Switzerland
Remibrutinib, as a BTK inhibitor, exerts immunomodulatory effects by blocking the B cell receptor signaling pathway and is clinically used for the treatment of autoimmune diseases. The drug interactions mainly involve the CYP3A metabolic enzyme system, and special attention should be paid to the risk of combination with potent inhibitors/inducers.
1. Effect of action
(1) Mechanism of action: Selective irreversible binding to BTK active sites, inhibiting B cell activation, proliferation, and autoantibody production, and reducing inflammatory response.
(2) Clinical efficacy: After 12 weeks of treatment for chronic spontaneous urticaria, the response rate reached 57%, and the itching symptom score was significantly improved (reducing by ≥ 4 points in 63% of cases).
(3) Effective time: The blood drug concentration reaches its peak within 2 hours, and clinical symptoms usually improve after 4-8 weeks of treatment. Continuous medication can maintain the therapeutic effect.
2 drug interactions
(1) CYP3A strong inhibitors, such as clarithromycin and itraconazole, may increase the blood concentration of Rabotinib and should be avoided in combination or reduced by 50%.
(2) CYP3A strong inducers, such as rifampicin and carbamazepine, may reduce efficacy and should be avoided in combination. If necessary, efficacy should be monitored and increments considered.
(3) Sensitive transporter substrates: When used in combination with P-gp/BCRP substrates (such as digoxin), the blood drug concentration of the latter needs to be monitored to prevent toxicity accumulation.
3 Special Interaction Management
(1) Anticoagulants: may enhance the effects of drugs such as warfarin, and INR values should be monitored weekly during combination therapy to adjust the dosage of anticoagulants.
(2) Immunosuppressants: Combination with JAK inhibitors may increase the risk of infection, and it is necessary to strengthen CMV/EB virus screening and lymphocyte count monitoring.
(3) Grapefruit products: contain CYP3A inhibitors, and should be avoided during treatment to prevent drug overdose.
Disclaimer：《The efficacy and drug interactions of Remibrutinib in Switzerland》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！